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Is antigen-specific suppression now unsuppressed?
Recent studies suggest that putative regulatory lymphocytes can effect
antigen-specific down-regulation of autoimmunity. But we have yet to see
how much this improves our picture of autoimmune disease progression.
The regulation of autoreactive T cells may in some
respects be modeled on the behaviour of the lac operon
of Escherichia coli, the essential paradigm for differential
gene regulation [1]. De-repression of the lac operon relies
on encounter with the primary target, lactose. But if
other factors - notably high glucose concentration -
keep or render cellular cyclic AMP levels low, the
catabolite activator protein that is required for maximal
transcription from the lac operon remains or becomes
inactive, and the de-repression of the operon is largely
ineffective, irrespective of lactose concentration. Like-
wise, although full activation of autoreactive lymphocytes
relies on encounter with the primary target, which is self
antigen, other factors that are operative at the time of, or
subsequent to, antigen exposure can conspire to reduce
or re-direct the lymphocytes' activity.
Given the potential therapeutic importance for people
with autoimmune diseases, what these regulatory 'other
factors' might be is a subject of intense interest. Recent
studies of rodent experimental autoimmune enceph-
alomyelitis (EAE), a demyelinating disease of the central
nervous system that is reminiscent of human multiple
sclerosis, indicate anew that the mystery factors may
include 'regulatory' lymphocytes. These findings offer an
attractive hypothesis, suggesting that it might be possible
to down-regulate autoimmune disease antigen-specifi-
cally, rather than through global immunosuppression.
The deletion of autoreactive T cells during development
of the thymus is not universal [2]. Such cells can enter
the peripheral immune system, but in most cases they
remain unactivated because there is no contact with self
antigens. However, injecting healthy rodents with com-
plete Freund's adjuvant containing either myelin basic
protein (MBP) or an MBP peptide can activate self-
MBP-reactive peripheral T cells. On activation, periph-
eral MBP-reactive T cells express on their surfaces the
integrins LFA-1 and VLA-4, which help them to cross
the endothelial lining of blood vessels and so get into tis-
sues [3]. If the T cells' antigenic target is expressed in a
tissue that they enter - for example, MBP is expressed
in the central nervous system - the T cells may prolifer-
ate in situ and elicit autoimmune disease. Thus, injection
of MBP can induce EAE in rodents (Fig. 1).
Activated T cells from rodents with MBP-induced EAE
can transfer the disease to recipient animals. In this way,
the 'culprit' class of T cells in EAE were shown usually
to be CD4-bearing cells, reactive to an MBP peptide
presented by specific class II alleles of the major histo-
compatibility complex (MHC). The suggestion that
CD4+ T cells are involved in EAE, as well as in other
autoimmune diseases such as type I diabetes, is consistent
with the observed linkage of disease penetrance to several
class II MHC alleles.
CD4+ T cells fall into at least two categories, Thl and
Th2. Activated Thl cells produce interleukin (IL)-2,
interferon y, and transforming growth factor (TGF)-oa
or -1; the combined action of these factors elicits inflam-
mation. Activated Th2 cells, by contrast, secrete IL-4,
which helps B cells to produce high-affinity antibodies of
certain isotypes, such as IgGl or IgE in mice. CD4+ T
cells can be biased towards a Thl fate if they are primed
by macrophages in the presence of IL-12, whereas pri-
ming by B cells biases them towards the Th2 fate. The
resulting commitment of a T-cell clone to becoming Thl
or Th2 seems relatively stable, both in vitro and in vivo.
Thus, cloned MBP-reactive Thl cells transfer disease,
whereas cloned MBP-reactive Th2 cells cannot [3]. A
Thl inflammatory response mounted in the central ner-
vous system elicits extensive cellular infiltration, leading
to loss of electrophysiological axonal integrity, and to the
animal's paralysis.
But other factors can counteract the pathogenic effects of
MBP-reactive Thl cells: in certain inbred strains of
rodents, MBP-induced EAE goes into spontaneous
remission. As MBP is abundant in the central nervous
system, this remission cannot be easily attributed to the
primary target of the Thl cells becoming limiting. So,
what are the other factors that suppress or re-direct the
inflammatory response? To date, the simplest system for
studying EAE uses mice transgenic for T-cell receptor
(TCR) genes taken from MBP-reactive encephalitogenic
Thl T-cell clones. In these mice, the inheritance of pre-
rearranged TCR transgenes largely precludes rearrange-
ment of the endogenous TCR genes, so that almost all
the T cells in these mice express the TCR characteristic
of the MBP-reactive T-cell clone.
Goverman et al. [4] reported that such mice are more
likely to develop EAE in response to injection of MBP, a
result which is to be expected given that the transgenic
mice house a greatly increased frequency of precursor T
cells reactive toward MBP. In addition, a fraction of the
transgenic mice developed EAE spontaneously when
they were kept in non-sterile conditions. The authors [4]
considered that instead of being triggered by MBP, the
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Fig. 1. How lymphocytes may act to promote (+) or suppress (-) autoimmune diseases such as EAE in the body's tissues. One can infer
that genetic and environmental factors that promote Th2 responses might oppose such diseases, whereas factors that increase the pre-
cursor frequency of autoreactive T cells might promote them.
T cells in these spontaneous EAE mice could have been
activated polyclonally, for example by bacterial superanti-
gens [5]. About 14 % of animals in an analogous set of
mice also developed EAE spontaneously, but in this case
the disease arose even though the mice were kept in 'spe-
cific-pathogen-free' conditions [6]. However, as the 'spe-
cific pathogens' that are routinely excluded in such
conditions were historically defined in relation to
immunocompetent mice, the transgenic mice may have
been positive for (and primed by) other organisms that
are not pathogenic for normal mice.
Alternatively, extravasation of virgin T cells into tissues,
which is usually assumed not to occur at all, may in fact
occur very occasionally: an extravasation rate of, say,
1 in 106 cells could permit about 100 virgin T cells to
enter tissues at any one time from a steady state peripheral
immune system containing perhaps 108 such cells. Such
extravasation might result from occasional spontaneous
expression of integrins, such as VLA4, which at such a
low frequency would be undetectable by any known
method for analysing cell-surface proteins in lymphocyte
populations. Occasional extravasation of virgin cells might
be a mechanism for routine irfmune surveillance, and
possibly for the developmental homing of epithelial lym-
phocytes. Ordinarily, there would be no consequences of
extravasation, as the chances are slim that T cells entering
a tissue would recognise self antigens therein. But if, as in
the TCR-transgenic mice, the frequency of precursor T
cells reactive toward the tissue is greatly exaggerated, an
autoreactive immune response could ensue in response to
even a low level of presented antigen.
Whatever the mechanism of 'spontaneous' priming in
the two sets of transgenic mice, the Thl phenotype is
in both cases preserved. Because allelic exclusion means
that both sets of transgenic mice have no other class of
oa3-TCR-bearing T cell, the results show that the
only oat-T cells required to initiate or maintain EAE
are CD4+ Thl cells. This point is taken one stage further
by Lafaille et al. [6], who crossed their TCR-transgenic
mice with mice congenitally lacking the recombinase
activating gene, RAG1. Because RAG1- /- mice cannot
undertake immunoglobulin-type gene rearrangement,
they contain no B cells or T cells. But the transgenically
driven MBP-reactive CD4+ T cells can develop, because
their TCR is encoded by pre-rearranged transgenes. The
finding that these mice, too, develop EAE shows that no
other lymphocyte is required for disease development.
Interestingly, the incidence of spontaneous EAE in these
mice is 100 %, with no remission occurring. In other
words, 'other factors' ameliorating disease are missing
from the immunodeficient, 'B-cell-less, T-cell-less'
RAG - /- mice, suggesting that the missing factors
include B or T lymphocytes.
A high incidence of autoimmune diseases in people with
immunodeficiencies, and in their relatives, was reported
over thirty years ago [7]. Thus, immunodeficiency may
itself be the problem that leads to autoimmune disease.
Infections that are not cleared may elicit chronic priming
of lymphocytes. Recent studies by Cyster et al. [8] indi-
cate that, in immunocompetent animals, autoreactive
lymphocytes may be unable to initiate autoimmune
responses because of competition from the full immune
repertoire for limited anatomical sites of activation. In
immunodeficient animals, by contrast, these sites would
be 'open'. Thus, RAG1-/ - , TCR-transgenic mice may
be more prone to disease because they are more immun-
odeficient, and so may prime the transgenic T cells more
readily. Alternatively, it might be the case, as it was
thought to be thirty years ago, that immunodeficiency
deprives an animal of regulatory lymphocytes that keep
autoreactive effector lymphocytes in check.
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The obvious difference between the RAG1+ /+ , MBP-
TCR transgenic mice and their RAG 1- /- counterparts is
the presence in the former of B cells. In an MBP immu-
nization of rats undertaken by Day et al. [9], priming of
MBP-reactive T cells by B cells rather than macrophages
was encouraged by co-administration of MBP peptide
coupled to anti-IgD. Almost no development of EAE
resulted. The authors considered that this was because
MBP presentation by B cells skewed the CD4+ T-cell
response towards Th2 and away from inflammatory tissue
damage. Interestingly, the spleen cells from the 'immu-
nized but protected' mice were able to transfer disease to
secondary recipients. This might lead to questions about
the current belief that the Thl and Th2 phenotypes are
relatively stable: perhaps the protected mice retained
uncommitted CD4+ T cells that were primed to Thl
activity in the secondary recipient.
Given this precedent, Lafaille et al. [6] hypothesize that
priming by MBP-reactive B cells shifts the balance in
some of the RAG1+/+ , TCR-transgenic mice towards a
non-pathogenic Th2 response. Certainly the healthy
RAG1'/+, TCR-transgenic mice showed little lympho-
cytic infiltration of the central nervous system. But how,
in the absence of antigen in the periphery, would rare
MBP-reactive B cells in a polyclonal repertoire prime the
transgenic T cells sufficiently early to affect the Thl:Th2
balance? The answer isn't obvious, but in such a simpli-
fied system the hypothesis can be tested, for example by
restoring B cells to the RAG1-/ - transgenic mice, or by
crossing the TCR transgene into a purely T-cell-deficient
genetic background.
Two other approaches have recently been taken in the
search for regulatory lymphocytes in EAE. In the first,
Sercarz and colleagues [10] isolated CD4+ T. cells that
are reactive to a peptide of the TCR of the predominant
anti-MBP encephalitogenic T cells, from mice with a
B1O.PL genetic background recovering from MBP-
induced EAE. Injection of such TCR-reactive cells into
B1O.PL mice, 24 hours before injection of MBP, largely
prevented EAE, strongly suggesting that the TCR-reac-
tive cells arising in mice undergoing remission are
natural and specific down-regulators of pathogenic
MBP-reactive T cells. Perhaps surprisingly, however, the.
reactive T-cell clones did not seem to affect other T cells
expressing exactly the same TCR variable region and
hence bearing the same epitope as the encephalitogenic
clones [10].
In a second approach, Chen et al. [11] isolated CD4+ ,
MBP-reactive T cells from mice with an SJL genetic
background that were fed low doses of MBP. The idea of
feeding the mice MBP is based on the observation that
we display tolerance to foreign proteins when we
encounter them as food. The result is that mice fed MBP
do not develop disease but instead gain oral tolerance
toward MBP, and this strategy is now being applied to
humans with multiple sclerosis [12]. The T-cell clones
that Chen et al. [11] isolated from the 'orally tolerized'
animals were able to suppress development of EAE in
recipient mice that were co-injected with MBP.
Interestingly, the T-cell clone's TCR usage was identical
to that of an encephalitogenic T-cell clone; the cells,
called 'Th3 cells' by Chen et al. [11], differed only in the
secretion of an unusual cytokine mixture of IL-4, IL-10,
and TGF-3. These data suggest that a single T-cell clone,
induced by distinct physiological mechanisms, can
oppose the activation of a sister pathogenic effector cell
type. As they use the same TCR as the encephalitogenic
clones, why don't cells of the type seen by Chen et al.
[11] develop in the TCR-transgenic mice, and thereby
suppress disease? Certainly one might predict that the
transgenic mice could be orally tolerized by the actions
of such T-cell clones.
What can we conclude about human multiple sclerosis
and other autoimmune diseases from these studies?
Having T-cell precursor frequencies skewed towards rec-
ognizing self antigens can clearly be a problem, and any
condition, either genetic or environmental, that encour-
ages such a situation is a potential disease-predisposing
condition. Thus, in the developed world, an increased
incidence of autoimmunity might be related to a delayed
and restricted exposure to pathogens and hence to a rela-
tively exaggerated autoreactive T-cell population. We
may also conclude that a single clone of autoreactive T
cells can be a potent effector of disease, although in real-
ity this is an unlikely scenario. In most cases, autoimmu-
nity is chronic, the effector immune response targeting
one self-antigen after another. Furthermore, recent stud-
ies have indicated that CD8+ T cells, as well as CD4+ T
cells, are critically involved in a murine model of auto-
immune diabetes [13,14].
We may also begin to conclude that during the evolu-
tion of the autoimmune response, lymphocytes arise
which are specific for either self-antigen or the autoreac-
tive T cells themselves, and which may oppose the
action of the pathogenic effector cells. While good news
for all of us, such cells have yet to be placed convin-
cingly into a scenario of disease remission. Moreover, if
such cells re-direct rather than abrogate an immune
response, the good news may only be temporary. In
autoimmune diabetes, the attack on the pancreas may be
induced by Thl cells reactive to the enzyme glutamic
acid decarboxylase (GAD), which is expressed in pan-
creatic islets and in a subset of neurons [15]. Re-direc-
tion of the inflammatory attack into a Th2 response may
spare the pancreas, but it may elicit a second serious
disease, stiff man syndrome, which is characterized by
high-titre antibodies against neuronal GAD. Translating
the new findings from rodent studies into safe thera-
peutic advances in the treatment of autoimmune disease
may take some time yet.
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